Evidence map›Paper›PMID 30191052›Full record

ReviewHepatic oncology2017

Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib.

Petros Giovanis, Graziano Pianezze, Valter Vincenzi, Carla Manuppelli, Massimo Boaretto, Davide Pastorelli

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hepatic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Petros GiovanisMedical Oncology Unit, City Hospital of Feltre, Via Bagnols Sul Ceze 3, 32032, Ulss 1 Dolomiti, Feltre, Italy.
Graziano PianezzeResearch Lab, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy.
Valter VincenziInternal Medicine & Hepatology, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy.
Carla ManuppelliInternal Medicine & Hepatology, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy.
Massimo BoarettoInternal Medicine & Hepatology, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy.
Davide PastorelliMedical Oncology Unit, City Hospital of Feltre, Via Bagnols Sul Ceze 3, 32032, Ulss 1 Dolomiti, Feltre, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimWe investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP). MATERIALS &

methodsCECs in advanced HCC patients receiving sorafenib were counted at baseline and every 4 weeks.

resultsTwenty four HCC patients were enrolled in the study. Median TTP was 3.2 months (1-6). Median baseline CEC levels were 67 cells/ml, with an increase of 169.8% after 4 weeks of treatment. Any time CEC levels in patients with a TTP lower than 4 months were higher, but not statistically significant, compared with those in patients with TTP more than 4 months.

conclusionTreatment with sorafenib changed CEC levels in HCC patients.

Indexed as

angiogenesis inhibitorsCECshepatocellular carcinomasorafenib

Identifiers

PMID30191052
PMCPMC6095409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.